Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly

Journal of Clinical Endocrinology and Metabolism

Volumn 76, Issue 3, 1993, Pages 721-727

  Heron, I ^a   Thomas, F ^b   Dero, M ^a   Gancel, A ^a   Ruiz, J M ^b   Schatz, B ^b   Kuhn, J M ^a  

^a UNIVERSITÉ DE ROUEN   (France)

^b IPSEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; LONG ACTING DRUG; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; GROWTH HORMONE BLOOD LEVEL; HORMONAL REGULATION; HUMAN; MALE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SUBCUTANEOUS DRUG ADMINISTRATION;

ACROMEGALY; ADULT; AGED; FEMALE; HUMAN; MALE; MIDDLE AGE; PEPTIDES, CYCLIC; SOMATOSTATIN; SUPPORT, NON-U.S. GOV'T; TIME FACTORS; TREATMENT OUTCOME;

EID: 0027457177     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jcem.76.3.8095269     Document Type: Article

References (45)

1. Melmed S. 1990 Acromegaly. N Engl J Med. 322:966-977.
2. Klibanski A, Zervas NT. 1991 Diagnosis and management of hormone secreting pituitary adenomas. N Engl J Med. 324:822-831.
3. Serri O, Somma M, Comtois R, et al. 1985 Acromegaly: biochemical assessment of cure after long term follow-up of transsphenoidal selective adenomectomy. J Clin Endocrinol Metab. 61:1185-1189.
4. Ludecke DK. 1988 Long-term surgical results in acromegaly. Does the immediate post-operative growth hormone level predict the outcome. Adv Biosci. 69:243-252.
5. Eastman RC, Gorden P, Roth J. 1979 Conventional supervoltage irradiation is an effective treatment for acromegaly. J Clin Endocrinol Metab. 48:931-940.
6. Quabbe HJ. 1982 Treatment of acromegaly by trans-sphenoidal operation, 90-yttrium implantation, and bromocriptine: results in 230 patients. Clin Endocrinol (Oxf). 16:107-119.
7. Grisoli F, Leclercq T, Jacquet P, et al. 1985 Transsphenoidal surgery for acromegaly-long term results in 100 patients. Surg Neurol. 25:513-519.
8. Ross DA, Wilson CB. 1988 Results of transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas in a series of 214 patients. J Neurosurg. 68:854-867.
9. Laws ER, Carpenter SM, Sheithauer BW, Randall RV. 1987 Long term results of transsphenoidal surgery for the management of acromegaly. In: Robbins R, Melmed S, eds. Acromegaly: a century of scientific and clinical progress. New York: Plenum Press; pp 241-248.
10. Vance ML, Harris AG. 1991 Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Arch Intern Med. 151:1573-1578.
11. Lamberts SWJ, Uitterlinden P, Verschoor L, van Dongen KJ, del Pozo E. 1985 Long term treatment of acromegaly with the somatostatin analog SMS 201-995. N Engl J Med. 313:1576-1580.
12. Quabbe HJ, Plockinger U. 1989 Dose-response study and longterm effect of the somatostatin analogue octreotide in patients with therapy-resistant acromegaly. J Clin Endocrinol Metab. 68:873-881.
13. Chiodini PG, Cozzi R, Dallabonanza D, et al. 1987 Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine. J Clin Endocrinol Metab. 64:447-453.
14. Halse J, Harris AG, Kvistborg A, et al. 1990 A randomized study of SMS 201-995 versus bromocriptine treatment in acromegaly: clinical and biochemical effects. J Clin Endocrinol Metab. 70:1254-12561.
15. Wang C, Lam KSL, Arceo E, Chan FL. 1989 Comparison of the effectiveness of 2-hourly versus 8-hourly subcutaneous injections of a somatostatin analog (SMS 201-995) in the treatment of acromegaly. J Clin Endocrinol Metab. 69:670-677.
16. Ch’ng LJC, Sandler LM, Kraenzlin ME, Burrin JM, Joplin GM, Bloom SR. 1985 Long-term treatment of acromegaly with a long-acting analogue of somatostatin. Br Med J. 290:284-285.
17. Barnard LB, Grantham WG, Lamberton P, O’Dorisio TM, Jackson IMD. 1986 Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201-995). Ann Intern Med. 105:856-861.
18. Comi RJ, Gorden P. 1987 The response of serum growth hormone levels to the long acting somatostatin analog SMS 201-995 in acromegaly. J Clin Endocrinol Metab. 64:37-42.
19. Barkan AL, Kelch RP, Hopwood NJ, Beitins IZ. 1988 Treatment of acromegaly with the long-acting somatostatin analogue SMS 201-995. J Clin Endocrinol Metab. 66:16-23.
20. Sassolas G, Harris AG, James-Deidier A, the French SMS 201995 acromegaly study group. 1990 Long term effect of incremental doses of the somatostatin analogue SMS 201-995 in 58 acromegalic patients. J Clin Endocrinol Metab. 71:391-397.
21. Moyse E, Le Dafniet J, Epelbaum J, et al. 1985 Somatostatin receptors in human growth hormone and prolactin secreting pituitary adenomas. J Clin Endocrinol Metab. 61:98-103.
22. Reubi JC, Landolt AM. 1984 High density of somatostatin receptors in pituitary tumors from acromegalic patients. J Clin Endocrinol Metab. 59:1148-1152.
23. Ikuyama S, Nawata H, Kato KI, Ibayashi H, Nakagaki H. 1986 Plasma growth hormone responses to somatostatin (SRIH) and SRIH receptors in pituitary adenomas in acromegalic patients. J Clin Endocrinol Metab. 62:729-733.
24. Reubi JC, Landolt AM. 1989 The growth hormone response to octreotide in acromegaly correlate with adenoma sandostatin receptors. J Clin Endocrinol Metab. 58:844-850.
25. Christensen SE, Weeke J, Orskov H, et al. 1987 Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients. Clin Endocrinol (Oxf). 27:297-306.
26. Timsit J, Chanson P, Larger E, et al. 1987 The effect of subcutaneous infusion versus subcutaneous injections of a somatostatin analogue (SMS 201-995) on the diurnal GH profile in acromegaly. Acta Endocrinol (Copenh). 116:108-112.
27. Tauber JP, Babin T, Tauber MT, et al. 1989 Long term effects of a continuous subcutaneous infusion of the somatostatin analogue octreotide in the treatment of acromegaly. J Clin Endocrinol Metab. 68:917-924.
28. Bauer W, Briner U, Doepfner W, et al. 1982 SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 3:1133-1140.
29. Lamberts SW. 1988 The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. Endocr Rev. 9:417-436.
30. Kuhn JM, Basin C, Emy P, et al. 1988 Effet d’un nouvel analogue de la somatostatine dans l’acromegalie. Ann Endocrinol (Paris). 49:37C.
31. 6 LHRH in man: sustained release polymer microsphere study (I.M. route). In: Prostate cancer, part A. New York: Liss; pp 435-437.
32. 6-luteinizing hormone-releasing hormone microcapsules. J Clin Endocrinol Metab. 62:670-677.
33. Sassolas G, Khalfallah Y, Chayvialle JA, et al. 1989 Effects of the somatostatin analog BIM 23014 on the secretion of growth hormone, thyrotropin, and digestive peptides in normal men. J Clin Endocrinol Metab. 68:239-246.
34. Jalil R, Nixon JR. 1990 Biodegradable poly(lactic acid) and poly(lactide-coglycolide) microcapsules: problems associated with preoperative techniques and release properties. J Microencapsulation. 7:297-325.
35. Rieu M, Girard F, Bricaire H, Binoux M. 1982 The importance of insulin-like growth factor (somatomedin) measurements in the diagnosis and surveillance of acromegaly. J Clin Endocrinol Metab. 55:147-153.
36. Lamberts SWJ, Uitterlinden P, Verleun T. 1987 Relationship between growth hormone and somatomedin-C levels in untreated acromegaly, after surgery and during medical therapy with sandostatin (SMS 201-995). Eur J Clin Invest. 17:354-359.
37. Chanson P, Timsit J, Masquet C, et al. 1990 Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Ann Intern Med. 113:921-925.
38. Gorden P, Comi RJ, Maton PN, Go VLW. 1989 Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary, gastrointestinal tract and non-neoplasic diseases of the gut. Ann Intern Med. 110:35-60.
39. McKnight JA, McCance DR, Crithers JG, Atkinson AB. 1989 Changes in glucose tolerance and development of gallstones during high dose treatment with octreotide for acromegaly. Br Med J. 299:604-605.
40. Comi RJ. 1989 Pharmacology and use in pituitary tumors. In: Gordon P, moderator. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med. 110:35-50.
41. van Liessum PA, Hopman WPM, Pieters GFFM, et al. 1989 Postprandial gallbladder motility during long-term treatment with the long-acting somatostatin analog SMS 201-995 in acromegaly. J Clin Endocrinol Metab. 69:557-562.
42. Ewins DL, Javaid A, Coskeran P, et al. 1991 Assessment of gallbladder dynamics and the development of gallstones during octreotide therapy for acromegaly. J Endocrinol Invest. 14(Suppl 1):43.
43. Gaskell E, Chayvialle JA, Mollard M, et al. 1991 Effets de l’analogue de la somatostatine et somatuline (BIM 23014) sur la sécrétion des hormones digestives de l’homme normal. Ann Endocrinol (Paris). 52:230.
44. Kuhn JM, Basin C, Mollard M, de Rougé B, Wolf LM. Effects of the new somatostatin analog (BIM 23014) on glucose homeostasis in normal men. Proc of the 72nd Annual Meet of the Endocrine Soc. 1990;51.
45. Kahn SE, Klaff LJ, Schwartz MW, et al. 1990 Treatment with a somatostatin analog decreases pancreatic β-cell and whole body sensitivity to glucose. J Clin Endocrinol Metab. 71:994-1002.